Primmune Therapeutics Presents Clinical Data from Phase 1 Study Evaluating PRTX007 in Healthy Volunteers at the 2023 American Association for the Study of Liver Diseases (AASLD) Annual Meeting

— PRTX007 demonstrated a favorable safety profile for all analyzed cohorts with no serious adverse events (SAEs) observed — — Well-controlled activation of innate and adaptive immune response observed without increases in proinflammatory factors — — Data support suitability of PRTX007 for investigation as a key component of combination therapy for curative treatment of chronic […] The post Primmune Therapeutics Presents Clinical Data from Phase 1 Study Evaluating PRTX007 in Healthy Volunteers at the 2023 American Association for the Study of Liver Diseases (AASLD) Annual Meeting appeared first